In writing about what attributes and skills qualify a scientist for a successful career in assay development for drug discovery, one characteristic that rarely gets discussed — but which is essential ...

Optimization of experimental assay design is crucial for the overall success of any drug discovery initiative. The factors that need to be considered include: selection of the most appropriate assay ...

The key statistical objective in IVD device evaluation is establishing performance criteria while minimizing bias and maximizing precision. While the statistical considerations and methodologies ...

Assays need to be specific for their research purpose, be that quantifying cellular levels of specific proteins, identification of potential new drug molecules, or quantitative measurements of levels ...

Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the ...

Drug resistance induced by paclitaxel and carboplatin plasmatic concentrations in lung cancer cell lines. This is an ASCO Meeting Abstract from the Markers in Cancer. This abstract does not include a ...

Friends of Cancer Research initiated a research partnership, inviting HRD assay developers to participate in two blinded analyses. In the first, 11 assay developers reported HRD status for the Cancer ...

Another major focus of my laboratory is to translate the mechanistic findings and the chemical biology tools into treatment strategies. These efforts encompass a large spectrum of activities such as ...

New Rochelle, NY, October 17, 2025—Mary Ann Liebert, Inc., is pleased that Wai Hong (Kevin) Lo, PhD, has been appointed the new Editor-in-Chief of the journal ASSAY and Drug Development Technologies.

Lateral flow assay applications have become increasingly diverse in a post-pandemic world, and the areas of infectious disease and oncology continue to be at the forefront. In both areas, the use of ...

"We are excited to make the HER1 and HER3 assays available for clinical development use," said William Young, president and CEO of Monogram Biosciences. "Our first VeraTag product, HERmark, is already ...